Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01293123 · ClinicalTrials.gov registry record · NA
Raltegravir Cerebrospinal Fluid Pharmacodynamic Study in HIV-Infected Individuals
A NA study, sponsored by University of California, San Diego.
- Terminated
- Registry status
- NA
- Development phase
- 2
- Enrollment target
NCT01293123 is a NA study that was terminated before completion, run by University of California, San Diego. The registered enrollment target is 2 participants.
The verdict
NCT01293123, a NA study, was terminated before completion, sponsored by University of California, San Diego.
- TERMINATED
- Registry status
- NA
- Development phase
- 2 participants
- Enrollment target
Study Summary
The primary aim of this study is to determine the effects of the HIV integrase inhibitor, raltegravir, in cerebrospinal fluid (CSF). This will be accomplished by collecting CSF before and after initiation of either raltegravir or another antiretroviral, efavirenz, each in combination with two other antiretrovirals. Assessments will include HIV RNA levels (viral load), neuropsychological testing, mood assessments, and quality of life assessments.
Interventions
- DRUG Efavirenz
- DRUG Raltegravir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2011-12 |
| Est. Completion | 2013-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01293123
The ClinicalTrials.gov registry entry for NCT01293123 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Efavirenz is the first listed.
NCT01293123 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01293123 about?
NCT01293123 is a clinical study titled "Raltegravir Cerebrospinal Fluid Pharmacodynamic Study in HIV-Infected Individuals". The primary aim of this study is to determine the effects of the HIV integrase inhibitor, raltegravir, in cerebrospinal fluid (CSF). This will be accomplished by collecting CSF before and after initiation of either raltegravir or another antiretroviral, efavirenz, each in combination with two other ...
What is the current status of trial NCT01293123?
This trial is currently terminated. It is a NA study. The enrollment target is 2 participants. The study started on 2011-12. Estimated completion is 2013-12.
What interventions are being tested in trial NCT01293123?
The interventions under investigation include: Efavirenz (DRUG), Raltegravir (DRUG).
Who is sponsoring clinical trial NCT01293123?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.